Lifecore Biomedical Q1 revenue falls 34%, misses analyst estimates

Lifecore Biomedical

06/05/2026 12:13

Overview

U.S. injectables CDMO's Q1 revenue fell 34% yr/yr, missing analyst expectations

Net loss per share widened to $0.43 from $0.42 yr/yr

Company reaffirmed 2026 revenue and adjusted EBITDA guidance

Outlook

Lifecore Biomedical expects 2026 revenue between $120 mln and $125 mln

Company sees 2026 Adjusted EBITDA between $20.5 mln and $25 mln

Company expects cost containment initiatives to drive margin improvement in 2026

Result Drivers

REVENUE DECLINE - Q1 revenue fell 34% yr/yr, with both CDMO and hyaluronic acid manufacturing segments posting significant decreases

COST CONTAINMENT - Operating expenses decreased 52% yr/yr due to ongoing cost reduction initiatives, per company

NEW PROGRAMS SIGNED - Three new commercial site transfer programs were signed in Q1, including with an existing customer and a medical aesthetics company

Company press release: ID:nGNX2YKdCn

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$23.20 mln
$26.50 mln (3 Analysts)
Q1 EPS
-$0.43


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Lifecore Biomedical Inc is $6.00, about 16.3% above its May 5 closing price of $5.16

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)